OTCMKTS:BSTG - Biostage Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.40 +0.05 (+2.13 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$2.35
Today's Range$2.40 - $2.40
52-Week Range$1.91 - $5.85
Volume134 shs
Average Volume2,288 shs
Market Capitalization$14.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.58
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Receive BSTG News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BSTG
CUSIPN/A
Phone774-233-7300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80,000.00
Book Value$0.78 per share

Profitability

Net Income$-11,910,000.00

Miscellaneous

Employees5
Market Cap$14.81 million
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable

Biostage (OTCMKTS:BSTG) Frequently Asked Questions

What is Biostage's stock symbol?

Biostage trades on the OTCMKTS under the ticker symbol "BSTG."

When is Biostage's next earnings date?

Biostage is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Biostage.

Has Biostage been receiving favorable news coverage?

News coverage about BSTG stock has trended positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biostage earned a news impact score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Biostage's key competitors?

What other stocks do shareholders of Biostage own?

Who are Biostage's key executives?

Biostage's management team includes the folowing people:
  • Mr. James J. McGorry, CEO & Director (Age 63)
  • Mr. Thomas W. McNaughton, CFO & Sec. (Age 59)
  • Yu Hong, Pres (Age 47)
  • Ms. Ginger A. Abraham-Freel, Director of Quality & Operations
  • Dr. William L. Fodor Ph.D., Chief Scientific Officer

How do I buy shares of Biostage?

Shares of BSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biostage's stock price today?

One share of BSTG stock can currently be purchased for approximately $2.40.

How big of a company is Biostage?

Biostage has a market capitalization of $14.81 million and generates $80,000.00 in revenue each year. Biostage employs 5 workers across the globe.

What is Biostage's official website?

The official website for Biostage is http://www.biostage.com.

How can I contact Biostage?

Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The company can be reached via phone at 774-233-7300 or via email at [email protected]


MarketBeat Community Rating for Biostage (OTCMKTS BSTG)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  35
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe BSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: What are gap-down stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel